These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9111708)

  • 1. The cost of depression in the elderly. Effects of drug therapy.
    Hughes D; Morris S; McGuire A
    Drugs Aging; 1997 Jan; 10(1):59-68. PubMed ID: 9111708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants.
    Bosmans JE; Brook OH; van Hout HP; de Bruijne MC; Nieuwenhuyse H; Bouter LM; Stalman WA; van Tulder MW
    Pharmacoeconomics; 2007; 25(1):25-37. PubMed ID: 17192116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressants in the elderly.
    Chiu HF
    Int J Clin Pract; 1997 Sep; 51(6):369-74. PubMed ID: 9489065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapy for geriatric depression.
    Bressler R; Katz MD
    Drugs Aging; 1993; 3(3):195-219. PubMed ID: 8324296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side effects, dropouts from treatment and cost consequences.
    Montgomery SA; Kasper S
    Int Clin Psychopharmacol; 1998 Feb; 13 Suppl 2():S1-5. PubMed ID: 9669192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.
    Flint AJ
    Drugs Aging; 1998 Oct; 13(4):269-80. PubMed ID: 9805208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.
    Henry JA; Rivas CA
    Pharmacoeconomics; 1997 Jun; 11(6):515-37. PubMed ID: 10168093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.
    Henry JA; Rivas CA
    Pharmacoeconomics; 1997 May; 11(5):419-43. PubMed ID: 10168031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of St John's Wort for the treatment of depression: the economic perspective.
    Solomon D; Ford E; Adams J; Graves N
    Aust N Z J Psychiatry; 2011 Feb; 45(2):123-30. PubMed ID: 20977305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic issues in the treatment of depression.
    Cohen LJ
    Formulary; 1995 Sep; 30 Suppl 1():S20-5. PubMed ID: 10151739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine. A pharmacoeconomic evaluation of its use in depression.
    Wilde MI; Whittington R
    Pharmacoeconomics; 1995 Jul; 8(1):62-81. PubMed ID: 10155603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antidepressant use in demented elderly subjects: current data].
    Bélicard-Pernot C; Manckoundia P; Ponavoy E; Rouaud O; Pfitzenmeyer P
    Rev Med Interne; 2009 Nov; 30(11):947-54. PubMed ID: 19299045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are psychological treatments for depression in primary care cost-effective?
    Bosmans JE; van Schaik DJ; de Bruijne MC; van Hout HP; van Marwijk HW; van Tulder MW; Stalman WA
    J Ment Health Policy Econ; 2008 Mar; 11(1):3-15. PubMed ID: 18424872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
    Sheehan DV; Wright-Etter PJ
    Manag Care Q; 2002; 10(3):21-31. PubMed ID: 12476662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal use of antidepressants in the elderly: a population-based study in Nova Scotia.
    Rojas-Fernandez C; Thomas VS; Carver D; Tonks R
    Clin Ther; 1999 Nov; 21(11):1937-50. PubMed ID: 10890265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.